Fig. 3From: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysisIncidence of global immune-related adverse events (irAEs) associated with anti-PD-1 and anti-PD-L1 antibodies: all grade (a) and severe grade (b). Organ-specific irAEs associated with anti-PD-1 and anti-PD-L1 antibodies (c)Back to article page